Bruker (BRKR) Set to Announce Earnings on Tuesday

Bruker (NASDAQ:BRKR) will issue its quarterly earnings data before the market opens on Tuesday, November 5th. Analysts expect the company to announce earnings of $0.61 per share for the quarter. Bruker has set its FY24 guidance at $2.59-2.64 EPS and its FY 2024 guidance at 2.590-2.640 EPS.Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Tuesday, August 6th. The medical research company reported $0.52 EPS for the quarter, hitting the consensus estimate of $0.52. Bruker had a net margin of 11.29% and a return on equity of 24.92%. The firm had revenue of $800.70 million for the quarter, compared to the consensus estimate of $799.44 million. During the same period last year, the firm posted $0.50 earnings per share. The business’s revenue was up 17.4% compared to the same quarter last year. On average, analysts expect Bruker to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Bruker Price Performance

BRKR stock opened at $59.29 on Monday. The firm has a market cap of $8.98 billion, a P/E ratio of 24.60, a P/E/G ratio of 2.21 and a beta of 1.20. The firm’s fifty day moving average is $64.23 and its 200 day moving average is $66.92. Bruker has a 52 week low of $55.12 and a 52 week high of $94.86. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.75 and a current ratio of 1.65.

Bruker Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, September 16th. Stockholders of record on Monday, September 2nd were paid a dividend of $0.05 per share. The ex-dividend date was Friday, August 30th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.34%. Bruker’s dividend payout ratio (DPR) is currently 8.30%.

Analyst Ratings Changes

Several equities research analysts recently weighed in on BRKR shares. Barclays started coverage on Bruker in a report on Tuesday, October 15th. They set an “overweight” rating and a $75.00 target price for the company. Wells Fargo & Company began coverage on shares of Bruker in a report on Tuesday, August 27th. They issued an “overweight” rating and a $78.00 target price on the stock. Wolfe Research lowered shares of Bruker from an “outperform” rating to a “peer perform” rating in a report on Monday, September 30th. Citigroup dropped their price target on shares of Bruker from $95.00 to $80.00 and set a “buy” rating for the company in a research report on Wednesday, July 10th. Finally, TD Cowen lowered their price objective on shares of Bruker from $74.00 to $72.00 and set a “hold” rating for the company in a research note on Wednesday, August 7th. One analyst has rated the stock with a sell rating, four have given a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, Bruker has an average rating of “Moderate Buy” and an average price target of $80.82.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.